What are the consensus estimates for TRANSCODE THERAPEUTICS INC (RNAZ) next earnings?
The consensus EPS estimate for the next earnings of TRANSCODE THERAPEUTICS INC (RNAZ) is -0.8 USD and the consensus revenue estimate is 0 USD.
TRANSCODE THERAPEUTICS INC (RNAZ) Forecast, Price Target & Analyst Ratings
NASDAQ:RNAZ • US89357L5012
Current stock price
9.785 USD
-0.02 (-0.15%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TRANSCODE THERAPEUTICS INC (RNAZ).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.80
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $9.79 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
RNAZ was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about RNAZ.
In the previous month the buy percentage consensus was at a similar level.
RNAZ was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-04-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-06-07 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.80
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 99.47%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A -100.00% | N/A | N/A 180.81% | N/A 86.69% | ||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -6.109M | -18.535M -203.43% | -19.295M -4.10% | -15.57M 19.31% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -384K | -456.9K -18.98% | -726.6K -59.03% | -6.151M -746.56% | -18.634M -202.93% | -19.419M -4.21% | -15.661M 19.35% | N/A 21.84% | N/A -36.67% | N/A -39.63% | N/A -14.41% | N/A 6.11% | N/A 42.28% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -61.45% | N/A 79.22% | -1,462.72 99.30% | N/A 99.70% | N/A 92.68% | N/A 25.00% | N/A -158.33% | N/A 6.45% | N/A 41.38% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | -0.80 99.47% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -3.468M 31.90% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.99%
EPS Next 5 Year
14.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
147.39%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
TRANSCODE THERAPEUTICS INC / RNAZ Forecast FAQ
What is the expected long term growth rate for RNAZ stock?
The expected long term growth rate for TRANSCODE THERAPEUTICS INC (RNAZ) is -25.99%.